These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22052369)

  • 1. Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms.
    Ferro M; Giuberti G; Zappavigna S; Perdonà S; Facchini G; Sperlongano P; Porto S; Di Lorenzo G; Buonerba C; Abbruzzese A; Altieri V; Caraglia M
    Oncol Rep; 2012 Feb; 27(2):409-15. PubMed ID: 22052369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer.
    Yang Y; Zhang LJ; Bai XG; Xu HJ; Jin ZL; Ding M
    Biomed Pharmacother; 2018 Oct; 106():1307-1316. PubMed ID: 30119201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial.
    Li R; Li Y; Song J; Gao K; Chen K; Yang X; Ding Y; Ma X; Wang Y; Li W; Wang Y; Wang Z; Dong Z
    BMC Urol; 2020 Jul; 20(1):97. PubMed ID: 32660456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer.
    Lightfoot AJ; Breyer BN; Rosevear HM; Erickson BA; Konety BR; O'Donnell MA
    Urol Oncol; 2014 Jan; 32(1):35.e15-9. PubMed ID: 23510863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells.
    Takeuchi H; Mmeje CO; Jinesh GG; Taoka R; Kamat AM
    Oncol Rep; 2015 Nov; 34(5):2738-44. PubMed ID: 26323344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer.
    Cockerill PA; Knoedler JJ; Frank I; Tarrell R; Karnes RJ
    BJU Int; 2016 Mar; 117(3):456-62. PubMed ID: 25682834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
    Addeo R; Caraglia M; Bellini S; Abbruzzese A; Vincenzi B; Montella L; Miragliuolo A; Guarrasi R; Lanna M; Cennamo G; Faiola V; Del Prete S
    J Clin Oncol; 2010 Feb; 28(4):543-8. PubMed ID: 19841330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer.
    Breyer BN; Whitson JM; Carroll PR; Konety BR
    Urol Oncol; 2010; 28(5):510-4. PubMed ID: 19171491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
    Ma Y; Yu WD; Trump DL; Johnson CS
    Cancer; 2010 Jul; 116(13):3294-303. PubMed ID: 20564622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience.
    Tuinmann G; Hegewisch-Becker S; Zschaber R; Kehr A; Schulz J; Hossfeld DK
    Anticancer Drugs; 2004 Jul; 15(6):575-9. PubMed ID: 15205599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro.
    Zoli W; Ricotti L; Tesei A; Ulivi P; Gasperi Campani A; Fabbri F; Gunelli R; Frassineti GL; Amadori D
    Clin Cancer Res; 2004 Feb; 10(4):1500-7. PubMed ID: 14977854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer.
    Daniels MJ; Barry E; Milbar N; Schoenberg M; Bivalacqua TJ; Sankin A; Kates M
    Urol Oncol; 2020 Feb; 38(2):40.e17-40.e24. PubMed ID: 31473090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of a c-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cells.
    Huang XL; Zhang H; Yang XY; Dong XY; Xie XY; Yin HB; Gou X; Lin Y; He WY
    Anticancer Drugs; 2017 Jul; 28(6):596-602. PubMed ID: 28430744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental study of combination therapy with S-1 against pancreatic cancer.
    Yoshizawa J; Takizawa A; Takeuchi O; Hiraku O; Sasaki K; Morimoto Y; Atsuda K; Inoue G; Suzuki Y; Asanuma F; Yamada Y
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1211-9. PubMed ID: 19337733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between gemcitabine and mitomycin-C in vitro.
    Aung TT; Davis MA; Ensminger WD; Lawrence TS
    Cancer Chemother Pharmacol; 2000; 45(1):38-42. PubMed ID: 10647499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Berberine enhances gemcitabine‑induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway.
    Gao X; Liu J; Fan D; Li X; Fang Z; Yan K; Fan Y
    Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34935059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Gemcitabine and Thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer/T-cell lymphoma.
    Chen M; Jiang Y; Cai X; Lu X; Chao H
    Int Immunopharmacol; 2021 Sep; 98():107829. PubMed ID: 34119916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
    Mey V; Giovannetti E; De Braud F; Nannizzi S; Curigliano G; Verweij F; De Cobelli O; Pece S; Del Tacca M; Danesi R
    Br J Cancer; 2006 Aug; 95(3):289-97. PubMed ID: 16868547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isodon eriocalyx and its bioactive component Eriocalyxin B enhance cytotoxic and apoptotic effects of gemcitabine in pancreatic cancer.
    Li L; Zhao SL; Yue GGL; Wong TP; Pu JX; Sun HD; Fung KP; Leung PC; Han QB; Lau CBS; Leung PS
    Phytomedicine; 2018 May; 44():56-64. PubMed ID: 29895493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
    Kornek GV; Schuell B; Laengle F; Gruenberger T; Penz M; Karall K; Depisch D; Lang F; Scheithauer W
    Ann Oncol; 2004 Mar; 15(3):478-83. PubMed ID: 14998852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.